155 related articles for article (PubMed ID: 38524636)
21. Onset of type 1 diabetes mellitus in two patients with maturity onset diabetes of the young.
Maltoni G; Zucchini S; Scipione M; Mantovani V; Salardi S; Cicognani A
Pediatr Diabetes; 2012 Mar; 13(2):208-12. PubMed ID: 21696527
[TBL] [Abstract][Full Text] [Related]
22. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups.
Yale JF; Bodholdt U; Catarig AM; Catrina S; Clark A; Ekberg NR; Erhan U; Holmes P; Knudsen ST; Liutkus J; Sathyapalan T; Schultes B; Rudofsky G
BMJ Open Diabetes Res Care; 2022 Apr; 10(2):. PubMed ID: 35383100
[TBL] [Abstract][Full Text] [Related]
23. MODY in Ukraine: genes, clinical phenotypes and treatment.
Globa E; Zelinska N; Elblova L; Dusatkova P; Cinek O; Lebl J; Colclough K; Ellard S; Pruhova S
J Pediatr Endocrinol Metab; 2017 Oct; 30(10):1095-1103. PubMed ID: 28862987
[TBL] [Abstract][Full Text] [Related]
24. A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes.
Nauck MA; Petrie JR; Sesti G; Mannucci E; Courrèges JP; Lindegaard ML; Jensen CB; Atkin SL;
Diabetes Care; 2016 Feb; 39(2):231-41. PubMed ID: 26358288
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive molecular analysis of Japanese patients with pediatric-onset MODY-type diabetes mellitus.
Yorifuji T; Fujimaru R; Hosokawa Y; Tamagawa N; Shiozaki M; Aizu K; Jinno K; Maruo Y; Nagasaka H; Tajima T; Kobayashi K; Urakami T
Pediatr Diabetes; 2012 Feb; 13(1):26-32. PubMed ID: 22060211
[TBL] [Abstract][Full Text] [Related]
26. HNF1A gene p.I27L is associated with early-onset, maturity-onset diabetes of the young-like diabetes in Turkey.
Beysel S; Eyerci N; Pinarli FA; Kizilgul M; Ozcelik O; Caliskan M; Cakal E
BMC Endocr Disord; 2019 May; 19(1):51. PubMed ID: 31109344
[TBL] [Abstract][Full Text] [Related]
27. Dipeptidyl peptidase-IV inhibitors are efficient adjunct therapy in HNF1A maturity-onset diabetes of the young patients--report of two cases.
Katra B; Klupa T; Skupien J; Szopa M; Nowak N; Borowiec M; Kozek E; Malecki MT
Diabetes Technol Ther; 2010 Apr; 12(4):313-6. PubMed ID: 20210571
[TBL] [Abstract][Full Text] [Related]
28. A novel HNF1B mutation p.R177Q in autosomal dominant tubulointerstitial kidney disease and maturity-onset diabetes of the young type 5: A pedigree-based case report.
Tao T; Yang Y; Hu Z
Medicine (Baltimore); 2020 Jul; 99(31):e21438. PubMed ID: 32756155
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
[TBL] [Abstract][Full Text] [Related]
30. Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real-world data from a diabetes out-patient clinic.
Hansen KB; Svendstrup M; Lund A; Knop FK; Vilsbøll T; Vestergaard H
Diabet Med; 2021 Oct; 38(10):e14655. PubMed ID: 34291491
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.
Lingvay I; Catarig AM; Frias JP; Kumar H; Lausvig NL; le Roux CW; Thielke D; Viljoen A; McCrimmon RJ
Lancet Diabetes Endocrinol; 2019 Nov; 7(11):834-844. PubMed ID: 31540867
[TBL] [Abstract][Full Text] [Related]
32. MODY5 Hepatocyte Nuclear Factor 1ß (HNF1ß)-Associated Nephropathy: experience from a regional monogenic diabetes referral centre in Singapore.
Hua Tan CS; Ang SF; Yeoh E; Goh BX; Loh WJ; Shum CF; May Ping Eng M; Yan Lun Liu A; Wan Ting Chan L; Goh LX; Subramaniam T; Sum CF; Lim SC
J Investig Med High Impact Case Rep; 2022; 10():23247096211065626. PubMed ID: 35038894
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States.
Hunt B; Hansen BB; Ericsson Å; Kallenbach K; Ali SN; Dang-Tan T; Malkin SJP; Valentine WJ
Adv Ther; 2019 Dec; 36(12):3483-3493. PubMed ID: 31650514
[TBL] [Abstract][Full Text] [Related]
34. Safety of Semaglutide.
Smits MM; Van Raalte DH
Front Endocrinol (Lausanne); 2021; 12():645563. PubMed ID: 34305810
[TBL] [Abstract][Full Text] [Related]
35. Diagnosis of hepatic nuclear factor 1A monogenic diabetes mellitus (HNF1A-MODY) impacts antihyperglycemic treatment.
Schnedl WJ; Holasek SJ; Schenk M; Enko D; Mangge H
Wien Klin Wochenschr; 2021 Mar; 133(5-6):241-244. PubMed ID: 33245425
[TBL] [Abstract][Full Text] [Related]
36. Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial.
Kapitza C; Dahl K; Jacobsen JB; Axelsen MB; Flint A
Diabetologia; 2017 Aug; 60(8):1390-1399. PubMed ID: 28526920
[TBL] [Abstract][Full Text] [Related]
37. HNF1B-MODY Masquerading as Type 1 Diabetes: A Pitfall in the Etiological Diagnosis of Diabetes.
Francis Y; Tiercelin C; Alexandre-Heyman L; Larger E; Dubois-Laforgue D
J Endocr Soc; 2022 Aug; 6(8):bvac087. PubMed ID: 35733830
[TBL] [Abstract][Full Text] [Related]
38. Prolonged episodes of hypoglycaemia in HNF4A-MODY mutation carriers with IGT. Evidence of persistent hyperinsulinism into early adulthood.
Bacon S; Kyithar MP; Condron EM; Vizzard N; Burke M; Byrne MM
Acta Diabetol; 2016 Dec; 53(6):965-972. PubMed ID: 27552834
[TBL] [Abstract][Full Text] [Related]
39. Real-world impact of once-weekly subcutaneous semaglutide after 2 years of follow-up: Results from a nationwide observational study in people with type 2 diabetes.
Vilsbøll T; Lindahl CØ; Nielsen NF; Tikkanen CK
Diabetes Obes Metab; 2023 Jun; 25(6):1740-1749. PubMed ID: 36809678
[TBL] [Abstract][Full Text] [Related]
40. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Frías JP; Davies MJ; Rosenstock J; Pérez Manghi FC; Fernández Landó L; Bergman BK; Liu B; Cui X; Brown K;
N Engl J Med; 2021 Aug; 385(6):503-515. PubMed ID: 34170647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
